Result of AGM

AI SummaryClose X

All resolutions proposed at the Annual General Meeting on 19 November 2026 were duly passed. The Company reaffirmed that lead candidate inzitagene plasmivec has demonstrated a favorable safety profile and clinically meaningful activity as monotherapy in a Phase 1 trial and in combination with checkpoint therapies in a Phase 2 trial; Modi-1 is currently being evaluated in a Phase 2 study in head and neck and renal cancers; and two GlyMab antibodies have been licensed to Genmab for further development.

Disclaimer*

UK 100

Latest directors dealings